NLS Pharmaceutics (NLSP) Key Ratios
$0.76
$-6.64
(-89.70%)
As on 30-Oct-2025 16:29EDT
Market cap
$4 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
4.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -13.93 | 69.20 | 19.19 | 3.96 |
| Net Profit | -- | -9.08 | 83.73 | 22.41 | 10.35 |
| EPS | -- | -1,042.40 | 85.19 | 12.32 | 13.74 |
| Book Value | -- | -- | -- | 108.91 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-24 | Dec-23 | Dec-22 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -123.72 | -10.07 | 53.34 | 438.42 | -862.92 |
| Return on Capital
| -57.78 | 49.86 | 68.38 | 621.18 | -862.92 |
| Return on Assets
| -178.43 | -235.54 | -97.10 | -218.86 | -219.34 |
| Debt to Equity (x)
| -- | -- | -- | -0.18 | -- |
Profitability
ROCE
68.38
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
68.38
|
621.18
|
-862.92
|
375.85
|
46.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
53.34
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
53.34
|
438.42
|
-862.92
|
283.03
|
37.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-97.10
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
-97.10
|
-218.86
|
-219.34
|
-342.48
|
-299.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
69.20
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
69.20
|
23.74
|
-30.54
|
-157.91
|
0.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
83.73
--
Year on year growth in profit after tax
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
83.73
|
26.21
|
-38.08
|
-317.49
|
47.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.85
--
Year on year growth in earnings per share
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
0.85
|
0.69
|
-11.81
|
-2.33
|
0.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
--
|
-0.18
|
--
|
--
|
-0.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
--
|
-0.18
|
--
|
4,609.19
|
-0.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.69
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
2.69
|
0.23
|
2.75
|
2.38
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
--
|
--
|
2.76
|
2.40
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-24.24
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
-24.24
|
-81.34
|
-153.49
|
-174.08
|
-19.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
--
|
-1,320.48
|
-1,277.38
|
-1,812.75
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
283,149.59
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
283,149.59
|
112,168.54
|
65,799.57
|
104,368.57
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-4.47
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
-4.47
|
-0.19
|
-0.12
|
-1.37
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
6.29
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
6.29
|
-0.25
|
0.62
|
30.18
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.98
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
NLS Pharmaceutics (NLSP)
|
-1.98
|
-0.25
|
0.45
|
-0.92
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
